Literature DB >> 21271256

[Antiangiogenic therapy at the ocular surface: when, what and why?].

F Bock1, B Regenfuss, C Cursiefen.   

Abstract

There are numerous indications for local antiangiogenic therapy at the ocular surface. These include vision-limiting corneal neovascularization, corneal blood and lymphatic vessels endangering corneal graft survival and tumor-associated lymphangiogenesis. A literature review in PubMed and own clinical and experimental data form the basis for a discussion of the indications, current therapeutic options and potential side-effects of local antiangiogenic therapy at the ocular surface.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21271256     DOI: 10.1007/s00347-010-2262-0

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  26 in total

Review 1.  Corneal (lymph)angiogenesis--from bedside to bench and back: a tribute to Judah Folkman.

Authors:  Birgit Regenfuss; Felix Bock; Anand Parthasarathy; Claus Cursiefen
Journal:  Lymphat Res Biol       Date:  2008       Impact factor: 2.589

Review 2.  Anti-VEGF therapy for glaucoma.

Authors:  Michael B Horsley; Malik Y Kahook
Journal:  Curr Opin Ophthalmol       Date:  2010-03       Impact factor: 3.761

Review 3.  [Inhibition of angiogenesis in the anterior chamber of the eye].

Authors:  F Bock; Y König; T Dietrich; P Zimmermann; M Baier; C Cursiefen
Journal:  Ophthalmologe       Date:  2007-04       Impact factor: 1.059

4.  Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis.

Authors:  Bjorn Bachmann; Rod S Taylor; Claus Cursiefen
Journal:  Ophthalmology       Date:  2010-06-03       Impact factor: 12.079

5.  Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study.

Authors:  Michael Küchle; Claus Cursiefen; Nhung X Nguyen; Achim Langenbucher; Berthold Seitz; Hartmut Wenkel; Peter Martus; Gottfried O H Naumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-06-21       Impact factor: 3.117

6.  Corneal neovascularization after nonmechanical versus mechanical corneal trephination for non-high-risk keratoplasty.

Authors:  Claus Cursiefen; Peter Martus; Nhung X Nguyen; Achim Langenbucher; Berthold Seitz; Michael Küchle
Journal:  Cornea       Date:  2002-10       Impact factor: 2.651

7.  Cellular-level characterization of lymph vessels in live, unlabeled corneas by in vivo confocal microscopy.

Authors:  Beatrice Bourghardt Peebo; Per Fagerholm; Catharina Traneus-Röckert; Neil Lagali
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-09-24       Impact factor: 4.799

8.  Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.

Authors:  Felix Bock; Jasmine Onderka; Tina Dietrich; Björn Bachmann; Friedrich E Kruse; Matthias Paschke; Grit Zahn; Claus Cursiefen
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-06       Impact factor: 4.799

9.  Intraocular lymphangiogenesis in malignant melanomas of the ciliary body with extraocular extension.

Authors:  Ludwig M Heindl; Tanja N Hofmann; Harald L J Knorr; Carmen Rummelt; Falk Schrödl; Ursula Schlötzer-Schrehardt; Leonard M Holbach; Gottfried O H Naumann; Friedrich E Kruse; Claus Cursiefen
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-17       Impact factor: 4.799

10.  Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.

Authors:  Felix Bock; Yanyan König; Friedrich Kruse; Martin Baier; Claus Cursiefen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-13       Impact factor: 3.117

View more
  2 in total

Review 1.  Emerging techniques to treat corneal neovascularisation.

Authors:  J Menzel-Severing
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

2.  [Pterygium: what about point of care biomarkers?]

Authors:  Alexander C Rokohl; Ludwig M Heindl; Claus Cursiefen
Journal:  Ophthalmologe       Date:  2021-05-31       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.